| Trial # | Type | Study Status | Status Date | Title |
|---|
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2021-03-04 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| INST University of Arizona 1807 | Breast Advanced | Open Active | 2020-02-17 | INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer |
| NRG Oncology NRG-BR004 | Breast Advanced | Open Active | 2019-09-24 | NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer |
| Pharm BO41843 | Breast Advanced | Open Active | 2021-04-26 | F. Hoffman-La Roche Ltd. BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Women with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-08-21 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| EA1181 | Breast Neoadjuvant | Open Active | 2020-05-14 | EA1181: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer) |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2020-11-05 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2019-03-27 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| SWOG S1703 | Breast Other | Open Active | 2020-04-28 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| Alliance A021502 | GI Colorectal Adjuvant | Open Active | 2021-01-21 | Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| NRG Oncology/SWOG NRG-GI004/SWOG-S1610 | GI Colorectal Advanced | Open Active | 2021-02-25 | NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2011-02-07 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| Alliance A041702 | Hematology Chronic Leukemia | Open Active | 2021-02-12 | Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2020-05-18 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| SWOG S1609 | Ill Defined | Open Active | 2021-04-02 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| UNM 1709 | Ill Defined | Open Active | 2019-07-02 | INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER) |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-01 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-26 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2021-04-05 | ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2019-08-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1C | Solid Tumors Other | Open Active | 2020-05-07 | ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2019-11-15 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2019-09-16 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1K | Solid Tumors Other | Open Active | 2019-07-29 | ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations |
| DCP-001 | Supportive | Open Active | 2017-05-24 | 1007 |
| DCP-001A | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001B | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001C | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001D | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| NRG Oncology NRG-BN003 | Brain Other | Open Active | 2017-10-20 | NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma |
| NCCTG N0577 | Brain Advanced | Open Active | 2017-12-18 | NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma |
| Alliance A071801 | Brain Advanced | Open Active | 2020-06-11 | Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease |
| Alliance A071701 | Brain Advanced | Open Active | 2020-04-17 | Alliance A071701: Genomically-Guided Treatment Trial in Brain Metastases |
| Pharm LNS-101 | Advanced Solid Tumors | Open Active | 2019-10-11 | Linnaeus Therapeutics LNS-101: A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab |
| ECOG-ACRIN EA1183 | Breast Advanced | Open Active | 2020-10-19 | ECOG-ACRIN EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE |
| Alliance A221505 | Breast Advanced | Open Active | 2018-04-10 | Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2021-03-04 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| Alliance A011801 | Breast Adjuvant | Open Active | 2021-05-17 | Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib |
| Alliance A011202 | Breast Adjuvant | Open Active | 2020-05-27 | Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
| NRG Oncology NRG-BR004 | Breast Advanced | Open Active | 2019-09-24 | NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer |
| INST University of Arizona 1807 | Breast Advanced | Open Active | 2019-10-24 | INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer |
| Pharm CA2097FL | Breast Advanced | Open Active | 2021-03-30 | Bristol-Myers Squibb CA2097FL: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer |
| Pharm BO41843 | Breast Advanced | Open Active | 2021-04-26 | F. Hoffman-La Roche Ltd. BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Women with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-09-05 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| SWOG S1501 | Breast Advanced | Open Active | 2020-11-20 | SWOG S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III |
| Pharm SGNLVA-002 | Breast Advanced | Open Active | 2018-02-20 | Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2019-06-24 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| EA1181 | Breast Neoadjuvant | Open Active | 2020-05-14 | EA1181: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer) |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2018-02-07 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| UNM 1607 | Breast Neoadjuvant | Open Active | 2018-04-16 | INST UNM 1607: Monitoring response to neoadjuvant chemotherapy (NAC) in Early Stage Breast Cancer (ESBC) Using High-speed MR Spectroscopic Imaging (MRSI) |
| Alliance A231701CD | CCDR | Open Active | 2020-07-10 | Alliance A231701CD: Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making through a Shared Decision Making Intervention |
| SWOG S1703 | Breast Other | Open Active | 2020-03-02 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| ECOG-ACRIN EA1151 | Breast Other | Open Active | 2018-08-31 | ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST) |
| CIBMTR Protocol for a Research Database | Epidemiological | Open Active | 2020-11-10 | CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
| WFU WF-30917CD | CCDR | Open Active | 2021-02-08 | WFU WF-30917CD: A Stepped-Care Telehealth Approach to Treat Distress in Cancer Survivors |
| UNM 1803 | Epidemiological | Open Active | 2018-06-26 | INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative |
| INST 1311 | Epidemiological | Open Active | 2017-06-20 | INST 1311: A Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation |
| Alliance A021502 | GI Colorectal Adjuvant | Open Active | 2018-10-12 | Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| UNM TCCP | Epidemiological | Open Active | 2017-12-08 | INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer |
| INST UNM 1809 | GI Colorectal Prevention | Open Active | 2018-12-27 | INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States |
| NRG Oncology/SWOG NRG-GI004/SWOG-S1610 | GI Colorectal Advanced | Open Active | 2021-02-25 | NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer |
| Alliance A021703 | GI Colorectal Advanced | Open Active | 2020-03-03 | Alliance A021703: Randomized Double-blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) |
| ECOG-ACRIN EA2174 | GI Esophageal Neoadjuvant | Open Active | 2021-05-28 | ECOG-ACRIN EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinom |
| SWOG S0820 | GI Colorectal Prevention | Open Active | 2017-10-05 | SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| Pharm 937-00 | GI Hepatic Adjuvant | Open Active | 2020-02-04 | Merck 937-00: A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) |
| PHARM CP-MGAH22-06 | GI Gastric Advanced | Open Active | 2020-03-13 | MacroGenics CP-MGAH22-06: A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-nave, HER2-Positive Gastric or Gastroesophageal Junction Cancer |
| Alliance A021602 | GI Other | Open Active | 2019-05-08 | Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) |
| ECOG-ACRIN EA2197 | GI Other | Open Active | 2021-05-28 | ECOG-ACRIN EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial |
| ECOG-ACRIN EA2165 | GI Other | Open Active | 2021-04-07 | ECOG-ACRIN EA2165: A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer |
| EA2185 | GI Other | Open Active | 2020-07-23 | EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs |
| SWOG S1820 | GI Other | Open Active | 2020-08-05 | SWOG S1820: A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC) |
| Pharm BO41932 | GI Other | Open Active | 2021-03-30 | Roche BO41932: Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial |
| Alliance A021806 | GI Pancreatic Adjuvant | Open Active | 2020-12-08 | Alliance A021806: A Phase III Trial Of Perioperative Versus Adjuvant Chemotherapy For Resectable Pancreatic Cancer |
| UNM 1603 | GI Other | Open Active | 2016-11-30 | INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health |
| Pharm FGCL-3019-087 | GI Pancreatic Advanced | Open Active | 2020-07-16 | FibroGen FGCL-3019-087: A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer |
| ECOG-ACRIN EA2186 | GI Pancreatic Advanced | Open Active | 2020-11-19 | ECOG-ACRIN EA2186: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Nave Metastatic Pancreatic Cancer (GIANT) |
| Pharm 905-00 | GU Other | Open Active | 2021-06-01 | Merck 905-00: A Phase 3 Randomized Study of Cystectomy plus Peri-operative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Patients with Muscle-invasive Bladder Cancer (KEYNOTE-905) |
| NRG-CC007CD | GU Other | Open Active | 2021-04-01 | NRG-CC007CD: Increasing The Dose Of Survivorship Care Planning In Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy |
| UNM 1805 | GU Other | Open Active | 2019-01-08 | INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors |
| SWOG S1823 | GU Other | Open Active | 2021-03-26 | SWOG S1823: A Prospective Observational Cohort Study To Assess Mirna 371 For Outcome Prediction In Patients With Newly Diagnosed Germ Cell Tumors |
| Pharm PrTK03 | GU Prostate Adjuvant | Open Active | 2017-06-28 | Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| Alliance A031704 | GU Renal Cell Advanced | Open Active | 2021-03-29 | Alliance A031704: PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated REnal cell cancEr (PDIGREE) |
| Pharm MK-7339-010 | GU Prostate Advanced | Open Active | 2020-02-10 | Merck MK-7339-010: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010) |
| NRG Oncology NRG-GU005 | GU Prostate Advanced | Open Active | 2018-01-29 | NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer |
| Alliance A031901 | GU Ureter Advanced | Open Active | 2021-05-25 | Alliance A031901: Duration Of Immune Checkpoint Therapy In Locally Advanced Or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial |
| RTOG 0724/GOG-0724 | GYN Cervical Adjuvant | Open Active | 2015-07-23 | RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2010-10-20 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| NRG-GY018 | GYN Endometrial Advanced | Open Active | 2020-12-10 | NRG Oncology NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer |
| Pharm Merck A18-00/ENGOT-cx11 | GYN Cervical Advanced | Open Active | 2021-03-03 | Merck A18-00/ENGOT-cx11: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11) |
| Pharm C-750-01/GOG-3028 | GYN Cervical Advanced | Open Active | 2019-11-14 | Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS |
| UNM 1509 | GYN Other | Open Active | 2020-06-29 | INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies |
| NCICOVID | GYN Other | Open Active | 2020-07-14 | NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study |
| NRG-GY021 | GYN Ovarian Advanced | Open Active | 2021-03-15 | NRG-GY021: A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer |
| NRG-GY009 | GYN Ovarian Advanced | Open Active | 2021-03-29 | NRG Oncology NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer |
| INST 1310 | Head And Neck Advanced | Open Active | 2015-02-25 | INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma |
| ECOG-ACRIN EA3161 | Head And Neck Advanced | Open Active | 2021-04-07 | ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA |
| VBL Therapeutics VB-111-701/GOG 3018 | GYN Ovarian Advanced | Open Active | 2019-08-29 | VBL Therapeutics VB-111-701/GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer |
| RTOG 1216 | Head And Neck Advanced | Open Active | 2020-07-24 | RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck |
| NRG Oncology NRG-HN004 | Head And Neck Advanced | Open Active | 2019-03-20 | NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin |
| Alliance A041501 | Hematology Acute Leukemia | Open Active | 2020-04-03 | Alliance A041501: A PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN (A CONJUGATED ANTI-CD22 MONOCLONAL ANTIBODY) TO FRONTLINE THERAPY IN YOUNG ADULTS (AGES 18-39 YEARS) WITH NEWLY DIAGNOSED PRECURSOR B-CELL ALL |
| NRG-HN005 | Head And Neck Other | Open Active | 2021-04-08 | NRG-HN005: A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer |
| UNM 1512 | Hematology Acute Leukemia | Open Active | 2018-05-23 | INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS |
| INST 0551C | Hematology Acute Leukemia | Open Active | 2016-05-02 | INST 0551C, Project 4 Dynamic Analysis of Signaling Networks in Leukemia |
| SWOG S1712 | Hematology Chronic Leukemia | Open Active | 2019-02-21 | SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease |
| Alliance A041702 | Hematology Chronic Leukemia | Open Active | 2020-08-07 | Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) |
| SWOG S1826 | Hematology Lymphoma Hodgkins | Open Active | 2021-03-24 | SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma |
| ECOG-ACRIN E4412 | Hematology Lymphoma Hodgkins | Open Active | 2021-04-14 | ECOG-ACRIN E4412: A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| Pharm INCB 18424-MA-GD-301 | Hematology Stem Cell Transplant | Open Active | 2019-01-29 | Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2020-05-18 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| SWOG S1803 | Hematology Myeloma | Open Active | 2019-11-14 | SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) |
| SWOG S1609 | Ill Defined | Open Active | 2021-04-02 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| INST 1306 | Ill Defined | Open Active | 2015-01-01 | INST 1306: Whole Genome Sequencing of Human Cancer Tissues |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-09 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| UNM 1709 | Ill Defined | Open Active | 2019-05-30 | INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER) |
| ECOG-ACRIN EA5182 | Lung NSCLC Advanced | Open Active | 2021-05-06 | ECOG-ACRIN EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-01 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| Pharm CX-839-014 | Lung NSCLC Advanced | Open Active | 2021-01-26 | CX-839-014: A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) |
| ECOG-ACRIN EA5191 | Lung NSCLC Advanced | Open Active | 2021-03-26 | ECOG-ACRIN EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-14 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| Pharm D910LC00001 | Lung NSCLC Advanced | Open Active | 2021-03-04 | AstraZeneca D910LC00001: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1) |
| SWOG S1933 | Lung NSCLC Advanced | Open Active | 2020-11-25 | SWOG S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status |
| SWOG S1914 | Lung NSCLC Advanced | Open Active | 2020-08-27 | SWOG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC |
| NRG Oncology NRG-CC003 | Lung SCLC Adjuvant | Open Active | 2020-08-24 | NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer |
| Alliance A081801 | Lung SCLC Adjuvant | Open Active | 2021-04-23 | Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO |
| Pharm M14-239 | Lung Other | Open Active | 2020-11-16 | AbbVie M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer |
| SWOG S1929 | Lung SCLC Advanced | Open Active | 2021-01-13 | SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
| NRG-LU005 | Lung SCLC Adjuvant | Open Active | 2020-02-05 | NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab |
| ECOG-ACRIN EA6141 | Skin Melanoma Advanced | Open Active | 2021-04-05 | ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2021-04-05 | ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial |
| SWOG S1801 | Skin Melanoma Advanced | Open Active | 2020-04-03 | SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2019-08-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-Z1C | Solid Tumors Other | Open Active | 2020-05-07 | ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2019-09-16 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2019-11-15 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1K | Solid Tumors Other | Open Active | 2019-07-29 | ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations |
| ECOG-ACRIN EAY131-Z1L | Solid Tumors Other | Open Active | 2019-07-29 | ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations |
| DCP-001A | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001C | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001B | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001 | Supportive | Open Active | 2016-08-17 | 1007 |
| Alliance A151804 | Supportive | Open Active | 2020-06-15 | Alliance A151804: Establishment of a National Biorepository to Advance Studies of Immune-related Adverse Events |
| INST DFCI-Harvard Cancer Center 16-477 | Supportive | Open Active | 2021-05-04 | INST DFCI-Harvard Cancer Center 16-477: The HOPE Trial and SMART Study |
| DCP-002 | Supportive | Open Active | 2017-11-16 | NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations |
| DCP-001D | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| WFU WF 97115 | Supportive | Open Active | 2017-07-06 | WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer |
| INST Johns Hopkins Hospital 1802 | Supportive | Open Active | 2019-09-20 | INST Johns Hopkins Hospital 1802: A Multi-Center Randomized Control Trial of Perioperative Palliative Care Surrounding Surgery for Patients and Their Family Members |
| WFU WF-1801 | Supportive | Open Active | 2019-09-27 | Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy |
